Dose-finding of PB-119 Administered Subcutaneously Once-weekly Versus Placebo in Drug-naïve T2DM Subjects
Status:
Completed
Trial end date:
2019-07-29
Target enrollment:
Participant gender:
Summary
This is a multicenter, randomized, double-blind, placebo-controlled, parallel dose cohort,
multiple dose study to evaluate the efficacy, safety, and tolerability of different doses of
PB-119 in drug-naïve subjects with T2DM.